title: [Paclitaxel].
abstract: The optimal dose and schedule of paclitaxel is not yet defined and is the subject of a number of clinical trials. These studies have not shown a clear-cut dose-response relationship. Trials evaluating administration schedule have not found either 24 h or 96 h infusion to be superior to 3 h infusion. These clinical evidence suggests that optimal dose and schedule of single-agent paclitaxel is 175 mg/m2 over 3 h. Weekly moderate-dose paclitaxel administration is generating much interest, as dose dense therapy, with very modest myelosuppression.
authors.affiliation: Department of Chemotherapy, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Omuro
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel